Immunochemotherapy containing rituximab for non-Hodgkin lymphoma caused pneumocystis pneumonia: three cases report and literature review
10.3760/cma.j.cn101721-20221025-000495
- VernacularTitle:含利妥昔单抗的免疫化疗治疗非霍奇金淋巴瘤并发肺孢子菌肺炎3例报告并文献复习
- Author:
Yu ZHANG
1
;
Wei LIU
;
Qing LENG
;
Jun GUAN
Author Information
1. 扬州大学附属苏北人民医院血液科，扬州 225000
- Keywords:
Rituximab;
Pneumocystis jirovecii Pneumonia;
Non-Hodgkins lymphoma
- From:
Clinical Medicine of China
2023;39(5):368-374
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the association of rituximab-containing immunochemotherapy for non-Hodgkin lymphoma and pneumocystis pneumonia.Methods:Retrospective analysis of case data of 3 patients admitted to the Subei People's Hospital with non-Hodgkin's lymphoma complicated with pneumocystis pneumonia during immunochemotherapy containing rituximab from 2020 to 2021 and reviewed the literature.Results:Three patients developed clinical manifestations of fever, dry cough and dyspnea 8 to 21 weeks after receiving R-CHOP regimen, chest CT showed ground-glass shadows or lung balloon,and pneumocystis jirovecii infection was confirmed after bronchoscopic alveolar lavage fluid, which improved after treatment with trimethoprim-sulfamethoxazole.Conclusion:Non-Hodgkin lymphoma patients receiving immunochemotherapy containing rituximab have low immunity during chemotherapy and are more likely to be complicated by pneumocystis pneumonia and short survival with poor prognosis. Therefore,it is necessary to be aware of this situation in the process of diagnosis and treatment. Early diagnosis and treatment and reasonable prevention are the key to improve prognosis and reduce mortality.
